Summary
Tranexamic Acid Market Research Report By Formulation Type (Oral Tablets, Injectable Solutions, Topical Applications), By Application (Post-Surgical Bleeding, Menorrhagia, Trauma Cases, Dental Procedures), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Home Care Settings), By Dosage Form (Low Dosage, Standard Dosage, High Dosage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) Forecast to 2035
Market Overview
The Global Tranexamic Acid Market is anticipated to experience substantial growth during the review period, with a compound annual growth rate (CAGR) of 5.38%. It is anticipated that the market will attain a value of USD 1,861.99 million by the conclusion of the forecast period (2025-2035), with an estimated value of USD 1,037.47 million in 2024.
The global tranexamic acid market is expanding at a rapid pace, primarily due to the increasing demand for hemostatic agents that are effective in medical, pharmaceutical, and cosmetic applications. Tranexamic acid is being used more frequently to prevent excessive bleeding during surgeries, trauma cases, and menstrual disorders, which is promoting its widespread adoption in hospitals, clinics, home care, and emergency care settings. Furthermore, the market is expanding due to the increasing recognition of the advantages of tranexamic acid in dermatology and cosmetics, particularly for the treatment of hyperpigmentation.
The market landscape is being transformed by technological advancements in drug formulations and delivery mechanisms, which have enabled enhanced bioavailability and therapeutic efficacy. Innovative formulations of tranexamic acid, including liposomal and nanoparticle-based formulations, are improving treatment outcomes while diminishing adverse effects. Furthermore, the market is experiencing growth because of the expansion of the scope of tranexamic acid in medical and aesthetic applications through the development of combination therapies that incorporate other active ingredients.
Market Segmentation Analysis
In 2024, the oral segment held a market share of 47.67% based on Formulation Type and is anticipated to grow at a compound annual growth rate (CAGR) of 5.83% during the forecast period. This is primarily motivated by its broad accessibility, affordability, and convenience. The substantial market share of oral tablets is a result of their widespread prescription for conditions such as excessive menstrual bleeding and surgical bleeding prevention.
In 2024, the hospitals & clinics segment held a market share of 45.25% based on End User and is anticipated to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period. The high volume of surgical procedures, trauma cases, and critical care treatments that necessitate tranexamic acid for hemorrhage management is the reason for this growth.
Analysis of the Region
In the global tranexamic acid (TXA) market, North America is the dominant region due to its advanced healthcare infrastructure, high volume of surgical procedures, and growing awareness of blood loss management. The United States and Canada have been at the forefront of TXA adoption as a result of the increasing number of trauma-related injuries, supportive regulatory policies, and the expansion of surgical interventions.
Europe is a mature and well-regulated TXA market, characterized by pervasive clinical adoption, strong government support, and well-established pharmaceutical manufacturing capabilities. TXA has been certified for a variety of medical applications by the European Medicines Agency (EMA) and national regulatory bodies, thereby guaranteeing standardized usage across healthcare institutions. The Asia-Pacific (APAC) region is experiencing rapid expansion in the tranexamic acid (TXA) market, which is being driven by expanding pharmaceutical production, high trauma incidences, rising maternal healthcare concerns, and increasing surgical volumes. Countries such as Germany are among those in this region. The adoption of TXA is being led by countries such as China, India, Japan, South Korea, and Australia, which are benefiting from an increasing number of clinical applications, growing awareness about blood loss management, and rising healthcare investments.
Major Players
Pfizer Inc., Fresenius Kabi AG, Teva Pharmaceuticals, Maxwellia Ltd, Aurobindo Pharma, Sun Pharma, Apotex Inc, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Exela Pharma Sciences are among the notable participants in the industry.
ページTOPに戻る
Table of Contents
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ............................................................................................................... 16
1.1 OVERVIEW .................................................................................................................................................................... 16
1.2 MARKET ATTRACTIVENESS ANALYSIS ........................................................................................................... 18
1.3 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE .......................................................... 19
1.4 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION ......................................................................... 20
1.5 GLOBAL TRANEXAMIC ACID MARKET, BY END USER ................................................................................. 21
1.6 GLOBAL TRANEXAMIC ACID MARKET, BY REGION ...................................................................................... 22
2 MARKET INTRODUCTION ............................................................................................................ 24
2.1 DEFINITION .................................................................................................................................................................. 24
2.2 SCOPE OF THE STUDY .............................................................................................................................................. 24
2.3 RESEARCH OBJECTIVE ............................................................................................................................................ 24
2.4 MARKET STRUCTURE .............................................................................................................................................. 24
3 RESEARCH METHODOLOGY ...................................................................................................... 25
3.1 OVERVIEW .................................................................................................................................................................... 25
3.2 DATA FLOW .................................................................................................................................................................. 27
3.2.1 Data Mining Process ....................................................................................................................................... 27
3.3 PURCHASED DATABASE: ......................................................................................................................................... 28
3.4 SECONDARY SOURCES: ............................................................................................................................................ 29
3.4.1 Secondary Research Data Flow: ....................................................................................................................... 30
3.5 PRIMARY RESEARCH: ............................................................................................................................................... 31
3.5.1 Primary Research Data Flow: .......................................................................................................................... 32
3.5.2 Primary Research: Number of Interviews conducted ........................................................................................ 33
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................................................................................... 34
3.6.1 Revenue Analysis Approach ............................................................................................................................ 34
3.7 DATA FORECASTING................................................................................................................................................. 35
3.7.1 Data forecasting Type ..................................................................................................................................... 35
3.8 DATA MODELING ........................................................................................................................................................ 36
3.8.1 Microeconomic Factor Analysis: ...................................................................................................................... 36
3.8.2 Data modeling: ............................................................................................................................................... 37
3.9 TEAMS AND ANALYST CONTRIBUTION ........................................................................................................... 38
4 MARKET DYNAMICS .................................................................................................................... 40
4.1 INTRODUCTION ........................................................................................................................................................... 40
4.2 GROWTH PARAMETERS MAPPED – DRIVERS ................................................................................................ 42
4.2.1 Increasing Surgical Procedures ....................................................................................................................... 42
4.2.2 Growing Prevalence of Trauma Cases .............................................................................................................. 43
4.2.3 Growing Prevalence of Heavy Menstrual Bleeding (HMB) .................................................................................. 43
4.3 WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS? ............................................... 45
4.3.1 Stringent Regulatory Requirements .................................................................................................................. 45
4.3.2 High R&D Costs for New Formulations ............................................................................................................. 46
4.4 MARKET OPPORTUNITIES MAPPED ................................................................................................................... 47
4.4.1 Rising Demand for Minimally Invasive & Non-Surgical Treatment Options .......................................................... 47
4.4.2 Untapped Potential in Emerging Markets ......................................................................................................... 48
5 MARKET FACTOR ANALYSIS ...................................................................................................... 49
5.1 PORTER’S FIVE FORCES MODEL ........................................................................................................................... 49
5.1.1 Bargaining Power of Suppliers ......................................................................................................................... 49
5.1.2 Bargaining Power of Buyers ............................................................................................................................ 50
5.1.3 Threat of New Entrants ................................................................................................................................... 50
5.1.4 Threat of Substitutes ...................................................................................................................................... 51
5.1.5 Intensity of Rivalry .......................................................................................................................................... 51
5.2 COVID-19 IMPACT ANALYSIS ................................................................................................................................ 52
5.2.1 Impact on R & D .............................................................................................................................................. 52
5.2.2 Impact on Supply Chain .................................................................................................................................. 52
5.2.3 Impact on Pricing ........................................................................................................................................... 53
6 GLOBAL TRANEXAMIC ACID MARKET, BY FORMULATION TYPE ............................................ 55
6.1 INTRODUCTION ........................................................................................................................................................... 55
6.2 ORAL ............................................................................................................................................................................... 57
6.3 INJECTABLE................................................................................................................................................................. 58
6.4 TROPICAL ...................................................................................................................................................................... 59
7 GLOBAL TRANEXAMIC ACID MARKET, BY APPLICATION ........................................................ 61
7.1 INTRODUCTION ........................................................................................................................................................... 61
7.2 MENORRHAGIA ........................................................................................................................................................... 63
7.3 SURGICAL BLEEDING CONTROL ............................................................................................................................ 65
7.4 TRAUMA AND INJURY ............................................................................................................................................ 66
7.5 HEREDITARY ANGIOEDEMA (HAE) ..................................................................................................................... 68
7.6 POSTPARTUM HEMORRHAGE .............................................................................................................................. 69
7.7 OTHERS .......................................................................................................................................................................... 70
8 GLOBAL TRANEXAMIC ACID MARKET, BY END USER ............................................................. 72
8.1 INTRODUCTION ........................................................................................................................................................... 72
8.2 HOSPITALS & CLINICS .............................................................................................................................................. 73
8.3 AMBULATORY SURGICAL CENTERS ................................................................................................................... 75
8.4 OTHERS .......................................................................................................................................................................... 76
9 GLOBAL TRANEXAMIC ACID MARKET, BY REGION.................................................................. 78
9.1 OVERVIEW .................................................................................................................................................................... 78
9.2 NORTH AMERICA ....................................................................................................................................................... 80
9.2.1 US.................................................................................................................................................................. 84
9.2.2 CANADA ........................................................................................................................................................ 85
9.3 EUROPE .......................................................................................................................................................................... 87
9.3.1 GERMANY ...................................................................................................................................................... 91
9.3.2 UK ................................................................................................................................................................. 92
9.3.3 FRANCE ......................................................................................................................................................... 94
9.3.4 ITALY ............................................................................................................................................................. 95
9.3.5 SPAIN ............................................................................................................................................................ 97
9.3.6 REST OF EUROPE ............................................................................................................................................ 98
9.4 ASIA-PACIFIC ............................................................................................................................................................... 100
9.4.1 CHINA ............................................................................................................................................................ 104
9.4.2 INDIA ............................................................................................................................................................. 105
9.4.3 JAPAN ........................................................................................................................................................... 107
9.4.4 SOUTH KOREA ................................................................................................................................................ 108
9.4.5 AUSTRALIA .................................................................................................................................................... 110
9.4.6 REST OF ASIA-PACIFIC ................................................................................................................................... 111
9.5 REST OF THE WORLD ................................................................................................................................................ 113
9.5.1 MIDDLE EAST ................................................................................................................................................. 117
9.5.2 AFRICA .......................................................................................................................................................... 118
9.5.3 LATIN AMERICA ............................................................................................................................................. 120
10 COMPETITIVE LANDSCAPE ........................................................................................................ 123
10.1 INTRODUCTION ........................................................................................................................................................... 123
10.2 MARKET SHARE ANALYSIS, 2024 ....................................................................................................................... 123
10.3 COMPETITION DASHBOARD ................................................................................................................................... 124
10.3.1 PRODUCT PORTFOLIO .................................................................................................................................... 124
10.3.2 REGIONAL PRESENCE ..................................................................................................................................... 125
10.3.3 STRATEGIC ALLIANCES .................................................................................................................................. 125
10.3.4 INDUSTRY EXPERIENCES ................................................................................................................................ 125
10.4 WHO ARE THE MAJOR DISRUPTORS & INNOVATORS ................................................................................. 125
10.5 WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS ........................................................ 126
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES ............................................................................................ 126
10.6.1 Merger and Acquisition ................................................................................................................................... 126
10.6.2 Product launch ............................................................................................................................................... 127
11 COMPANY PROFILES .................................................................................................................. 128
11.1 PFIZER INC .................................................................................................................................................................... 128
11.1.1 COMPANY OVERVIEW ..................................................................................................................................... 128
11.1.2 FINANCIAL OVERVIEW .................................................................................................................................... 129
11.1.3 PRODUCTS OFFERED ...................................................................................................................................... 129
11.1.4 KEY DEVELOPMENTS ...................................................................................................................................... 130
11.1.5 SWOT ANALYSIS ............................................................................................................................................ 130
11.1.6 Key Strategy ................................................................................................................................................... 130
11.2 FRESENIUS KABI USA, LLC ..................................................................................................................................... 131
11.2.1 COMPANY OVERVIEW ..................................................................................................................................... 131
11.2.2 FINANCIAL OVERVIEW .................................................................................................................................... 132
11.2.3 PRODUCTS OFFERED ...................................................................................................................................... 132
11.2.4 KEY DEVELOPMENTS ...................................................................................................................................... 132
11.2.5 SWOT ANALYSIS ............................................................................................................................................ 133
11.2.6 Key Strategy ................................................................................................................................................... 133
11.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. .................................................................................................. 134
11.3.1 COMPANY OVERVIEW ..................................................................................................................................... 134
11.3.2 FINANCIAL OVERVIEW .................................................................................................................................... 135
11.3.3 PRODUCTS OFFERED ...................................................................................................................................... 135
11.3.4 KEY DEVELOPMENTS ...................................................................................................................................... 135
11.3.5 SWOT ANALYSIS ............................................................................................................................................ 136
11.3.6 Key Strategy ................................................................................................................................................... 136
11.4 MAXWELLIA LTD. ...................................................................................................................................................... 137
11.4.1 COMPANY OVERVIEW ..................................................................................................................................... 137
11.4.2 PRODUCTS OFFERED ...................................................................................................................................... 138
11.4.3 KEY DEVELOPMENTS ...................................................................................................................................... 138
11.4.4 SWOT ANALYSIS ............................................................................................................................................ 139
11.4.5 Key Strategy ................................................................................................................................................... 139
11.5 AUROBINDO PHARMA USA .................................................................................................................................... 140
11.5.1 COMPANY OVERVIEW ..................................................................................................................................... 140
11.5.2 PRODUCTS OFFERED ...................................................................................................................................... 141
11.5.3 KEY DEVELOPMENTS ...................................................................................................................................... 141
11.5.4 SWOT ANALYSIS ............................................................................................................................................ 141
11.5.5 Key Strategy ................................................................................................................................................... 142
11.6 SUN PHARMACEUTICAL INDUSTRIES LTD. ..................................................................................................... 143
11.6.1 COMPANY OVERVIEW ..................................................................................................................................... 143
11.6.2 FINANCIAL OVERVIEW .................................................................................................................................... 144
11.6.3 PRODUCTS OFFERED ...................................................................................................................................... 144
11.6.4 KEY DEVELOPMENTS ...................................................................................................................................... 144
11.6.5 SWOT ANALYSIS ............................................................................................................................................ 145
11.6.6 Key Strategy ................................................................................................................................................... 145
11.7 APOTEX INC. ................................................................................................................................................................ 146
11.7.1 COMPANY OVERVIEW ..................................................................................................................................... 146
11.7.2 PRODUCTS OFFERED ...................................................................................................................................... 147
11.7.3 KEY DEVELOPMENTS ...................................................................................................................................... 147
11.7.4 SWOT ANALYSIS ............................................................................................................................................ 148
11.7.5 Key Strategy ................................................................................................................................................... 148
11.8 FERRING PHARMACEUTICALS ............................................................................................................................. 149
11.8.1 COMPANY OVERVIEW ..................................................................................................................................... 149
11.8.2 PRODUCTS OFFERED ...................................................................................................................................... 150
11.8.3 KEY DEVELOPMENTS ...................................................................................................................................... 150
11.8.4 SWOT ANALYSIS ............................................................................................................................................ 150
11.8.5 Key Strategy ................................................................................................................................................... 151
11.9 NORDIC PHARMA, INC .............................................................................................................................................. 152
11.9.1 COMPANY OVERVIEW ..................................................................................................................................... 152
11.9.2 PRODUCTS OFFERED ...................................................................................................................................... 153
11.9.3 KEY DEVELOPMENTS ...................................................................................................................................... 153
11.9.4 SWOT ANALYSIS ............................................................................................................................................ 153
11.9.5 Key Strategy ................................................................................................................................................... 154
11.10 EXELA PHARMA SCIENCES LLC ........................................................................................................................... 155
11.10.1 COMPANY OVERVIEW ..................................................................................................................................... 155
11.10.2 PRODUCTS OFFERED ...................................................................................................................................... 156
11.10.3 KEY DEVELOPMENTS ...................................................................................................................................... 156
11.10.4 SWOT ANALYSIS ............................................................................................................................................ 156
11.10.5 Key Strategy ................................................................................................................................................... 157
12 DATA CITATIONS ......................................................................................................................... 158
